Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.92
-0.08-2.67%
At close: -
$2.82
-0.10-3.46%
After Hours: Apr 3, 6:57 PM EDT
Comments
Loading...
Senti Biosciences Analyst Ratings and Price Targets | NASDAQ:SNTI | Benzinga
Senti Biosciences Inc has a consensus price target of $7 based on the ratings of 4 analysts. The high is $12 issued by Chardan Capital on December 4, 2024. The low is $2 issued by Morgan Stanley on March 24, 2023. The 3 most-recent analyst ratings were released by Chardan Capital on December 4, 2024, December 2, 2024, and August 15, 2023, respectively. With an average price target of $9.33 between Chardan Capital, there's an implied 231.09% upside for Senti Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Morgan Stanley
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Senti Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/04/2024 | Buy Now | 325.68% | Chardan Capital | Geulah Livshits44% | $10 → $12 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 254.74% | Chardan Capital | Geulah Livshits44% | $10 → $10 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 112.84% | Chardan Capital | Geulah Livshits44% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 112.84% | Chardan Capital | Geulah Livshits44% | $70 → $60 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | -29.05% | Morgan Stanley | Michael Ulz59% | $30 → $20 | Maintains | Equal-Weight | Get Alert |
| 03/23/2023 | Buy Now | 148.32% | Chardan Capital | Geulah Livshits44% | $80 → $70 | Maintains | Buy | Get Alert |
| 01/30/2023 | Buy Now | 183.79% | Chardan Capital | Geulah Livshits44% | $120 → $80 | Maintains | Buy | Get Alert |
| 01/27/2023 | Buy Now | 6.42% | Morgan Stanley | Michael Ulz59% | $75 → $30 | Maintains | Equal-Weight | Get Alert |
| 12/16/2022 | Buy Now | — | JP Morgan | Brian Cheng34% | — | Initiates | → Neutral | Get Alert |
| 10/07/2022 | Buy Now | 166.05% | Morgan Stanley | Michael Ulz59% | → $75 | Initiates | → Equal-Weight | Get Alert |
| 09/29/2022 | Buy Now | 148.32% | B of A Securities | Greg Harrison42% | → $70 | Initiates | → Buy | Get Alert |
| 09/23/2022 | Buy Now | 325.68% | Chardan Capital | Geulah Livshits44% | → $120 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Senti Biosciences (SNTI) stock?
The latest price target for Senti Biosciences (NASDAQ:SNTI) was reported by Chardan Capital on December 4, 2024. The analyst firm set a price target for $12.00 expecting SNTI to rise to within 12 months (a possible 325.68% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Senti Biosciences (SNTI)?
The latest analyst rating for Senti Biosciences (NASDAQ:SNTI) was provided by Chardan Capital, and Senti Biosciences maintained their buy rating.
When was the last upgrade for Senti Biosciences (SNTI)?
There is no last upgrade for Senti Biosciences
When was the last downgrade for Senti Biosciences (SNTI)?
There is no last downgrade for Senti Biosciences.
When is the next analyst rating going to be posted or updated for Senti Biosciences (SNTI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Senti Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Senti Biosciences was filed on December 4, 2024 so you should expect the next rating to be made available sometime around December 4, 2025.
Is the Analyst Rating Senti Biosciences (SNTI) correct?
While ratings are subjective and will change, the latest Senti Biosciences (SNTI) rating was a maintained with a price target of $10.00 to $12.00. The current price Senti Biosciences (SNTI) is trading at is $2.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.